Back to search

Article

“Endothelial antibody factory” at the Blood Brain Barrier: novel approach to therapy of neurodegenerative diseases

2022-03-01

Abstract excerpt

<title>Abstract</title> <p>Phase III clinical trials of immunotherapies against Alzheimer’s disease have failed to hit major endpoints. Despite the high doses administered, small fractions of injected monoclonal antibodies cross the blood brain barrier (BBB), likely resulting in an antibody concentration in the brain parenchyma that is too low for a therapeutic effect. Here we report a novel approach to circumven...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7bca38d5-c33b-554c-bbcc-f301333264ae
DOI
10.21203/rs.3.rs-1325519/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
“Endothelial antibody factory” at the Blood Brain Barrier: novel approach to therapy of neurodegenerative diseasesDOI 10.21203/rs.3.rs-1325519/v1
Select a neighboring publication to make it the new centre.